Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae

被引：59

作者：

Betriu, C ^{[1
]}

Culebras, E ^{[1
]}

Gómez, M ^{[1
]}

Rodríguez-Avial, I ^{[1
]}

Sánchez, BA ^{[1
]}

Agreda, MC ^{[1
]}

Picazo, JJ ^{[1
]}

机构：

[1] Hosp Clin San Carlos, Dept Clin Microbiol, Madrid 28040, Spain

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 03期

关键词：

D O I：

10.1128/AAC.47.3.1112-1114.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The rates of resistance to erythromycin and clindamycin among Streptococcus agalactiae strains isolated in our hospital increased from 4.2 and 0.8% in 1993 to 17.4 and 12.1%, respectively, in 2001. Erythromycin resistance was mainly due to the presence of an Erm(B) methylase, while the M phenotype was detected in 3.8% of the strains. Telithromycin was very active against erythromycin-resistant strains, irrespective of their mechanisms of macrolide resistance.

引用

页码：1112 / 1114

页数：3

共 21 条

[1] Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere [J].

Andrews, JI ;

Diekema, DJ ;

Hunter, SK ;

Rhomberg, PR ;

Pfaller, MA ;

Jones, RN ;

Doern, GV .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 183 (04) :859-862

[2]

[Anonymous], 1996, MMWR Recomm Rep, V45, P1

[3]

Barry AL, 2001, EUR J CLIN MICROBIOL, V20, P494

[4] ANTIBIOTIC-RESISTANCE AND PENICILLIN TOLERANCE IN CLINICAL ISOLATES OF GROUP-B STREPTOCOCCI [J].

BETRIU, C ;

GOMEZ, M ;

SANCHEZ, A ;

CRUCEYRA, A ;

ROMERO, J ;

PICAZO, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2183-2186

[5] Macrolide and tetracycline resistance and molecular relationships of clinical strains of Streptococcus agalactiae [J].

Culebras, E ;

Rodriguez-Avial, I ;

Betriu, C ;

Redondo, M ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1574-1576

[6] Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada [J].

de Azavedo, JCS ;

McGavin, M ;

Duncan, C ;

Low, DE ;

McGeer, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) :3504-3508

[7] Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae:: French multicenter study [J].

De Mouy, D ;

Cavallo, JD ;

Leclercq, R ;

Fabre, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2400-2402

[8] Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis [J].

Fernandez, M ;

Hickman, ME ;

Baker, CJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1517-1519

[9] High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan [J].

Hsueh, PR ;

Teng, LJ ;

Lee, LN ;

Ho, SW ;

Yang, PC ;

Luh, KT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3205-3208

[10] In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species [J].

Jalava, J ;

Kataja, J ;

Seppälä, H ;

Huovinen, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :789-793

← 1 2 3 →